Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.22 (-0.77%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk
Goldman Fans Can Reap Returns From S&P 500 ETFs in 2022
by Sanghamitra Saha
Goldman Sachs (GS) this week said that it expects the S&P 500 to rise 9% to 5,100 by the end of 2022, as quoted on a Yahoo Finance article.
Atea (AVIR) Plunges on Termination of Collaboration With Roche
by Zacks Equity Research
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up
by Zacks Equity Research
J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.
Pre-Markets Edge Up on JNJ Split News
by Zacks Equity Research
Pre-Markets Edge Up on JNJ Split News
J&J Plans to Split in Two; Dow Up Triple Digits
by Mark Vickery
In order to focus on market growth in its Pharma division, Johnson & Johnson now plans to split its Consumer Health business into a separate entity.
Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill's Strong Efficacy
by Kinjel Shah
AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
by Zacks Equity Research
Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
7 Stocks With Triple-Digit Gains Powering S&P 500 ETF
by Sweta Killa
The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.
The Stock Market Rally Is Back In High Gear
by Daniel Laboe
All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) third-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
5 ETFs Sizzling to Start November
by Sweta Killa
ETFs overall gathered about $20 billion capital last week (ending Nov 5), bringing in inflows of more than $739 billion year to date.
Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially
Markets Up on COVID Pill News
by Zacks Equity Research
Markets Up on COVID Pill News
More Good Covid Treatment News; Markets Up Again
by Mark Vickery
The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.
Rally in Travel and Tourism ETFs Set to Continue
by Sweta Killa
The solid trend in travel and tourism ETFs are likely to continue heading into the holiday season given the reopening of domestic and international borders for traveling.
Stock Market News for Nov 8, 2021
by Zacks Equity Research
Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.